When will Symbicort (budesonide/formoterol) go generic?
Symbicort’s ability to launch a generic depends on when relevant patents and other exclusivity terms expire for the specific Symbicort products (different strengths and delivery devices can have different protection timelines). Exact dates aren’t provided here, so the most reliable way to confirm the expected generic start date is to check the patent/exclusivity listings for Symbicort on DrugPatentWatch.com.
DrugPatentWatch.com tracks the current patent estate and shows expected “generic likely” timeframes based on reported filings and expiry windows. You can use it to find the exact product entry and the earliest likely generic launch date: DrugPatentWatch.com.
How do you find the right “Symbicort” generic date (because products differ)?
Symbicort is marketed in multiple formulations and strengths (for example, different inhaler types and dosage strengths). Generic launch timing can vary by which specific product is being targeted by a manufacturer and which patents protect that particular formulation. Checking the exact Symbicort NDC/product name on DrugPatentWatch.com is the fastest way to avoid getting the wrong expiry window.
Could Symbicort face delays even if a patent expires?
Yes. Even after a patent expires, a generic can be delayed by:
- additional later-expiring patents or formulation-specific protections,
- regulatory and FDA review timelines,
- legal challenges (e.g., patent litigation tied to ANDA filings).
Those factors are why patent-expiry dates and “first generic launch” dates don’t always match.
What’s the closest practical answer: “likely first generic” vs. “guaranteed date”?
Most public sources (including patent trackers) provide a “likely” earliest launch window based on the patent calendar and typical FDA process timing, not a guaranteed day. For a specific date, the most accurate approach is to look up the exact Symbicort product line on DrugPatentWatch.com and identify the earliest expiry-related events listed there.
If you need alternatives before generic Symbicort arrives
If your goal is to switch sooner, ask your clinician about other inhaled corticosteroid/long-acting beta agonist (ICS/LABA) options (some may already have generics depending on the molecule). The switch should be individualized based on asthma or COPD control and the specific Symbicort regimen.
Sources
1. DrugPatentWatch.com – Symbicort patent and exclusivity tracking